Yifan Li1, Weiwei Cheng1, Bin Zhao1, Dongliang Ma1, Xing Wei1, Shunye Zhang2. 1. Department of Cardiovascular Surgery, Shanxi Cardiovascular Hospital, Taiyuan, PR of China. 2. Department of Cardiovascular Surgery, Shanxi Cardiovascular Hospital, Taiyuan, PR of China. Email: 956980086@qq.com.
Abstract
OBJECTIVES: Epicardial adipose tissue (EAT) aromatase converts androstenedione and other adrenal androgens into oestrogens. The locally produced oestradiol (E2) may have cardiovascular protective effects. Little is known about the relationship between EAT aromatase level and coronary heart disease (CHD). Here, we compared EAT aromatase levels in CHD versus non-CHD patients and assessed the relationship between EAT aromatase levels and lesion degree in the coronary arteries. METHODS: EAT and blood specimens were obtained from patients undergoing thoracotomy prior to cardiopulmonary bypass. Serum E2 levels were obtained from our hospital laboratory. EAT aromatase expression was determined by RT-qPCR and ELISA assays. All patients underwent coronary angiography and the level of coronary lesions was evaluated with the SYNTAX score. RESULTS: Compared with non-CHD patients, CHD patients had lower EAT aromatase mRNA and protein levels. In the CHD patients, EAT aromatase and oestrogen levels negatively correlated with the severity of coronary artery disease. CONCLUSIONS: Our data revealed that reduced EAT aromatase levels correlated with coronary atherosclerotic lesions. Reduced EAT aromatase protein levels may aggravate the severity of atherosclerosis. Future studies should investigate the mechanisms regulating aromatase expression in epicardial fat.
OBJECTIVES: Epicardial adipose tissue (EAT) aromatase converts androstenedione and other adrenal androgens into oestrogens. The locally produced oestradiol (E2) may have cardiovascular protective effects. Little is known about the relationship between EAT aromatase level and coronary heart disease (CHD). Here, we compared EAT aromatase levels in CHD versus non-CHD patients and assessed the relationship between EAT aromatase levels and lesion degree in the coronary arteries. METHODS: EAT and blood specimens were obtained from patients undergoing thoracotomy prior to cardiopulmonary bypass. Serum E2 levels were obtained from our hospital laboratory. EAT aromatase expression was determined by RT-qPCR and ELISA assays. All patients underwent coronary angiography and the level of coronary lesions was evaluated with the SYNTAX score. RESULTS: Compared with non-CHD patients, CHD patients had lower EAT aromatase mRNA and protein levels. In the CHD patients, EAT aromatase and oestrogen levels negatively correlated with the severity of coronary artery disease. CONCLUSIONS: Our data revealed that reduced EAT aromatase levels correlated with coronary atherosclerotic lesions. Reduced EAT aromatase protein levels may aggravate the severity of atherosclerosis. Future studies should investigate the mechanisms regulating aromatase expression in epicardial fat.
Authors: Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong Journal: Circulation Date: 2008-12-15 Impact factor: 29.690
Authors: Tomasz Mazurek; LiFeng Zhang; Andrew Zalewski; John D Mannion; James T Diehl; Hwyda Arafat; Lea Sarov-Blat; Shawn O'Brien; Elizabeth A Keiper; Anthony G Johnson; Jack Martin; Barry J Goldstein; Yi Shi Journal: Circulation Date: 2003-10-27 Impact factor: 29.690